Comprehensive Liquid Biopsy Analysis for Monitoring NSCLC Patients Under Second-line Osimertinib Treatment

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Nov 5

PMID 39497713

Authors

Aliki Ntzifa

Theodoros Marras

Galatea Kallergi

Athanasios Kotsakis

Vasilis Georgoulias

Evi Lianidou

Affiliations

Soon will be listed here.

Abstract

Background: The heterogeneous and complex genetic landscape of NSCLC impacts the clinical outcomes of patients who will eventually develop resistance to osimertinib. Liquid biopsy (LB) analysis as a minimally invasive approach is a key step to efficiently identify resistance mechanisms and adjust to proper subsequent treatments.

Materials And Methods: In the present study, we combined plasma-cfDNA and CTC analysis from 30 NSCLC patients in samples collected before treatment and at the progression of disease (PD). We detected molecular alterations at the DNA mutation ( G12C, V600E), DNA methylation ( and ), gene expression (, and ) and chromosomal level ( and amplification) as possible resistance mechanisms and druggable targets. We also studied the expression of PD-L1 in single CTCs using immunofluorescence.

Results: In some cases, T790M resistance mutation was detected at baseline in CTCs but not in the corresponding plasma cfDNA. mutations were detected only in plasma-cfDNA but not in corresponding CTCs. G12C and V600E mutations were not detected in the samples analyzed. amplification was detected in the CTCs of two patients before treatment whereas amplification was detected in the CTCs of three patients at baseline and in one patient at PD. DNA methylation analysis revealed low concordance between CTCs and cfDNA, indicating the complementary information obtained through parallel LB analysis. Results from gene expression analysis indicated high rates of vimentin-positive CTCs detected at all time points during osimertinib. Moreover, there was an increased number of NSCLC patients at PD harboring CTCs positive in and expression detected in CTCs during treatment suggesting new possible therapeutic strategies.

Discussion: Our results reveal that comprehensive liquid biopsy analysis can efficiently represent the heterogeneous molecular landscape and provide prominent information on subsequent treatments for NSCLC patients at PD since druggable molecular alterations were detected in CTCs.

Citing Articles

Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.

Liao Y, Tsai C, Huang H Cancers (Basel). 2025; 17(3).

PMID: 39941826 PMC: 11815769. DOI: 10.3390/cancers17030459.

References

Hata A, Niederst M, Archibald H, Gomez-Caraballo M, Siddiqui F, Mulvey H . Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016; 22(3):262-9. PMC: 4900892. DOI: 10.1038/nm.4040. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Jebbink M, de Langen A, Monkhorst K, Boelens M, van den Broek D, van der Noort V . Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target Bypass Track Resistance in Mutation-Positive NSCLC. JTO Clin Res Rep. 2023; 4(4):100481. PMC: 10074240. DOI: 10.1016/j.jtocrr.2023.100481. View

Huang Y, Gan J, Guo K, Deng Y, Fang W . Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and Trametinib Combination Therapy. J Thorac Oncol. 2019; 14(10):e236-e237. DOI: 10.1016/j.jtho.2019.05.040. View

Herbst R, Wu Y, John T, Grohe C, Majem M, Wang J . Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023; 41(10):1830-1840. PMC: 10082285. DOI: 10.1200/JCO.22.02186. View

Kapeleris J, Kulasinghe A, Warkiani M, OLeary C, Vela I, Leo P . culture of circulating tumour cells derived from non-small cell lung cancer. Transl Lung Cancer Res. 2020; 9(5):1795-1809. PMC: 7653113. DOI: 10.21037/tlcr-20-521. View

Meng P, Koopman B, Kok K, Ter Elst A, Schuuring E, van Kempen L . Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation. Lung Cancer. 2020; 146:358-361. DOI: 10.1016/j.lungcan.2020.05.036. View

Chimonidou M, Strati A, Malamos N, Georgoulias V, Lianidou E . SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin Chem. 2012; 59(1):270-9. DOI: 10.1373/clinchem.2012.191551. View

El Kadi N, Wang L, Davis A, Korkaya H, Cooke A, Vadnala V . The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer. Cancer Res. 2018; 78(24):6728-6735. PMC: 6295274. DOI: 10.1158/0008-5472.CAN-17-3370. View

10.

de Jong D, Das J, Ma H, Pailey Valiplackal J, Prendergast C, Roa T . Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer. Cancers (Basel). 2023; 15(10). PMC: 10216085. DOI: 10.3390/cancers15102855. View

11.

Liu H, Vuppalapaty M, Wilkerson C, Renier C, Chiu M, Lemaire C . Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients. Front Oncol. 2020; 10:572895. PMC: 7578230. DOI: 10.3389/fonc.2020.572895. View

12.

Hou T, Ma J, Hu C, Zou F, Jiang S, Wang Y . Decitabine reverses gefitinib resistance in PC9 lung adenocarcinoma cells by demethylation of RASSF1A and GADD45β promoter. Int J Clin Exp Pathol. 2020; 12(11):4002-4010. PMC: 6949799. View

13.

Cross D, Ashton S, Ghiorghiu S, Eberlein C, Nebhan C, Spitzler P . AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4(9):1046-61. PMC: 4315625. DOI: 10.1158/2159-8290.CD-14-0337. View

14.

Yang J, Ahn M, Kim D, Ramalingam S, Sequist L, Su W . Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017; 35(12):1288-1296. DOI: 10.1200/JCO.2016.70.3223. View

15.

Stergiopoulou D, Markou A, Strati A, Zavridou M, Tzanikou E, Mastoraki S . Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer. Sci Rep. 2023; 13(1):1258. PMC: 9870904. DOI: 10.1038/s41598-022-25400-1. View

16.

Nguyen H, Cao N, Nguyen T, Le K, Nguyen D, Nguyen Q . Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations. Sci Rep. 2021; 11(1):16436. PMC: 8361064. DOI: 10.1038/s41598-021-95985-6. View

17.

Ntzifa A, Lianidou E . Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis. Crit Rev Clin Lab Sci. 2023; 60(8):573-594. DOI: 10.1080/10408363.2023.2230290. View

18.

Kim D, Bach D, Fan Y, Luu T, Hong J, Park H . AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells. Cell Death Dis. 2019; 10(5):361. PMC: 6494839. DOI: 10.1038/s41419-019-1601-6. View

19.

Martignano F, Munagala U, Crucitta S, Mingrino A, Semeraro R, Del Re M . Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients. Mol Cancer. 2021; 20(1):32. PMC: 7881593. DOI: 10.1186/s12943-021-01327-5. View

20.

Passaro A, Malapelle U, Del Re M, Attili I, Russo A, Guerini-Rocco E . Understanding EGFR heterogeneity in lung cancer. ESMO Open. 2020; 5(5):e000919. PMC: 7569934. DOI: 10.1136/esmoopen-2020-000919. View